Atossa Genetics (NASDQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions.
Atossa Genetics Announces Warrant Exercises
Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study
Atossa Genetics to Present at the LD Micro Invitational on June 6, 2017
More Press Releases
Learn more about Atossa Genetics
Learn more about our programs
Contact Atossa Genetics today!